studies

428A AASLD ABSTRACTS HEPATOLOGY, October, 2015
was significantly higher in group 3 (13.5% vs. 6.7% vs. 55%,
P=0.014) with lower incidence of solid organ metastasis (60%
vs. 23.1% vs. 18.6%, P=0.001) and CP class B (70%, 50%,
25.4%%, P=0.001) compared to group 2 and 1. In univariate
cox analysis, treatment modalities, presence of either lymph
node or other organ metastasis, CP class B, and decrease in
AFP levels were associated with survival. However, multivariate
analysis revealed that treatment modalities (group 1 vs.
2, HR, 0.244; 95% CI, 0.06-0.999, P=0.05, group 1 vs. 3,
HR, 0.121; 95% CI 0.028-0.51, P=0.004 and group 2 vs.
3, HR 0.495; 95% CI, 0.25-0.98, P=0.044) and decrease in
serum AFP level within 2 months of treatment (HR, 1.813; 95%
CI, 1.204-2.72; P=0.004) were the only independent factors
associated with survival. Median OS was significantly higher
in patient treated with radiotherapy (group3, 11.1 months)
than group 2 (3.6 months, log rank P